Skip to main content
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Ph 3/4 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

view all Clinical Trials

Overview

The purpose of the study is two-fold: (1) to further evaluate the safety and potential immunogenicity of GLASSIA following IV administration via in-line filtration; and, (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 mg/kg Body weight (BW)/week active A1PI protein for 25 weeks in subjects with emphysema due to congenital A1PI deficiency.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu or call 215-707-1359.